Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Keratoacanthomas associated with sorafenib therapy.

× No keyword cloud information.

3 in total

1. BAY 43-9006 inhibition of oncogenic RET mutants.

Authors: Francesca Carlomagno; Suresh Anaganti; Teresa Guida; Giuliana Salvatore; Giancarlo Troncone; Scott M Wilhelm; Massimo Santoro
Journal: J Natl Cancer Inst Date: 2006-03-01 Impact factor: 13.506

2. Keratoacanthoma in a sub-tropical climate.

Authors: J J Sullivan; G A Colditz
Journal: Australas J Dermatol Date: 1979-04 Impact factor: 2.875

Review 3. Raf kinase inhibitors in oncology.

Authors: Dirk Strumberg; Siegfried Seeber
Journal: Onkologie Date: 2005-02

3 in total

18 in total

1. New onset of multiple keratoacanthomas and palmoplantar hyperkeratosis caused by the treatment of metastatic renal cell carcinoma with a new generation multi-kinase inhibitor.

Authors: Jasper Mesarch; John Rupp; Nasir Zaidi
Journal: BMJ Case Rep Date: 2009-12-09

Review 2. [Actinic keratosis, Bowen's disease, keratoacanthoma and squamous cell carcinoma of the skin].

Authors: M Majores; E Bierhoff
Journal: Pathologe Date: 2015-02 Impact factor: 1.011

3. Sorafenib-induced eruptive melanocytic lesions.

Authors: Heidi H Kong; Vincent Sibaud; Maria L Chanco Turner; Tito Fojo; Thomas J Hornyak; Christine Chevreau
Journal: Arch Dermatol Date: 2008-06

4. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.

Authors: Harina Vin; Grace Ching; Sandra S Ojeda; Charles H Adelmann; Vida Chitsazzadeh; David W Dwyer; Haiching Ma; Karin Ehrenreiter; Manuela Baccarini; Rosamaria Ruggieri; Jonathan L Curry; Ana M Ciurea; Madeleine Duvic; Naifa L Busaidy; Nizar M Tannir; Kenneth Y Tsai
Journal: Mol Cancer Ther Date: 2013-10-29 Impact factor: 6.261

5. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Authors: Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach
Journal: J Am Acad Dermatol Date: 2012-05-18 Impact factor: 11.527

6. Sorafenib Induced Hand-Foot Skin Reaction at Low Dose.

Authors: Vrutika H Shah; Bhagyashree B Supekar; Rajesh P Singh; Jayesh I Mukhi
Journal: Indian Dermatol Online J Date: 2020-09-19

7. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].

Authors: L M Ehmann; V Heinemann; A Wollenberg
Journal: Internist (Berl) Date: 2011-11 Impact factor: 0.743

8. Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors: Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal: Oncologist Date: 2013-03-01

9. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.

Authors: Zita Dubauskas; Joy Kunishige; Victor G Prieto; Eric Jonasch; Patrick Hwu; Nizar M Tannir
Journal: Clin Genitourin Cancer Date: 2009-01 Impact factor: 2.872

10. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors: Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531